Can-Fite in R&D pact with NIH

The focus of the pact will be to identify agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.

Petah Tikva-based Can-Fite BioPharma said Tuesday it signed a cooperative research and development Agreement with the National Institute of Health in the US. The agreement relates to new small molecules that are agonists of the A(3) adenosine receptor A(3)AR, invented in the laboratory of Prof. Kenneth A. Jacobson from, which is the prime target of Can-Fite's drug development efforts. The focus of the pact will be to identify agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.